Valuation: Simulations Plus, Inc.

Market Cap 371M 321M 301M 274M 515M 35.49B 524M 3.53B 1.38B 17.77B 1.39B 1.36B 59.06B P/E 2026 *
43.7x
P/E 2027 * 40.1x
Enterprise Value 371M 321M 301M 274M 515M 35.49B 524M 3.53B 1.38B 17.77B 1.39B 1.36B 59.06B EV / Sales 2026 *
4.53x
EV / Sales 2027 * 4.3x
Free-Float
83.09%
Yield 2026 *
-
Yield 2027 * -
1 day+0.25%
1 week+0.19%
Current month+0.69%
1 month+0.69%
3 months+37.59%
6 months+49.35%
Current year+0.69%
1 week 18.3
Extreme 18.3
18.37
1 month 18.19
Extreme 18.19
18.39
Current year 11.09
Extreme 11.09
21.01
1 year 11.09
Extreme 11.09
21.01
3 years 11.09
Extreme 11.09
51.22
5 years 11.09
Extreme 11.09
67.59
10 years 7.9
Extreme 7.9
90.92
Manager TitleAgeSince
Chief Executive Officer 67 2018-06-25
Director of Finance/CFO 63 2020-11-30
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 81 1996-07-16
Director/Board Member 58 2014-12-02
Chairman 76 2024-12-16
Date Insider Type Main position Quantity % Market Cap.
8/3/26 Sell

Executive/Senior Manager

-1,000 0.0050%
7/6/26 Sell

Executive/Senior Manager

-1,000 0.0050%
7/1/26 Sell

Founder

-4,177 0.0207%
Change 5-day change 1-year change 3-year change Capi.($)
+0.25%+0.19%+28.90%-60.96% 371M
-3.52%+5.76%-13.14%+26.98% 39.6B
-2.28%-1.05%-45.00%+146.54% 13.25B
+1.72%+5.91%-18.62%+66.69% 5.74B
+35.70%+46.01%+35.00% - 3.66B
+4.06%+8.99% - - 2.01B
-0.90%+1.33%+17.70%-41.20% 1.7B
-3.16%-5.28%-40.41% - 967M
+1.97%+0.86%+38.78%+130.05% 924M
-0.82%+0.28%-32.47%-45.83% 836M
Average +3.30%+6.81%-3.25%+31.75% 6.9B
Weighted average by Cap. -0.36%+7.05%-16.18%+54.18%

Financials

2026 *2027 *
Net sales 81.87M 70.71M 66.45M 60.43M 114M 7.83B 115M 779M 304M 3.92B 307M 301M 13.03B 86.26M 74.5M 70.01M 63.67M 120M 8.25B 122M 820M 321M 4.13B 324M 317M 13.73B
Net income 9.53M 8.23M 7.74M 7.04M 13.23M 912M 13.45M 90.66M 35.45M 457M 35.79M 35.02M 1.52B 10.18M 8.79M 8.26M 7.51M 14.13M 974M 14.36M 96.82M 37.86M 488M 38.23M 37.4M 1.62B
Net Debt - -
Logo Simulations Plus, Inc.
Simulations Plus, Inc. specializes in model-informed and artificial intelligence (AI)-accelerated drug development. The Company helps its clients by accelerating the discovery, development, and commercialization of pharmaceuticals and other products through science-based software and consulting solutions. The Company’s segments include Software and Services. The Company's Software segment supports pharmaceutical research, development, and commercialization through simulation, modeling, and AI-driven prediction. Its main products include GastroPlus, ADMET Predictor, MonolixSuite, and others for disease modeling and training, as well as Pro-ficiency for clinical operations. Its Services segment includes advanced consulting services across the entire drug development lifecycle. Its scientists and engineers specialize in drug discovery, pharmacokinetics, pharmacodynamics, drug modeling, clinical trial data analysis, regulatory strategy, and medical communications.
Employees
213
Date Price Change Volume
26-08-14 US$18.35 +0.22% 214,624
26-08-13 US$18.31 -0.05% 151,224
26-08-12 US$18.32 +0.05% 182,253
26-08-11 US$18.31 -0.22% 247,707
26-08-10 US$18.35 +0.16% 195,010
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
5
Last Close Price
18.35USD
Average target price
17.25USD
Spread / Average Target
-5.99%

Quarterly revenue - Rate of surprise